AIM ImmunoTech Inc.

As of March 31, 2026, AIM ImmunoTech Inc. carries a market capitalization of 4.56M, placing it among publicly traded companies globally. Its enterprise value stands at 3.25M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

AIM ImmunoTech Inc.'s next confirmed earnings release is scheduled for November 17, 2026.

As of March 31, 2026, AIM ImmunoTech Inc. has 8.22M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 15.15, and the price-to-book ratio stands at 2.14.

These figures are as of March 31, 2026. The EV/Sales ratio of 34.58 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.25M versus a market cap of 4.56M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, AIM ImmunoTech Inc. maintains a current ratio of 1.01, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 215.25, indicating elevated leverage, while an interest coverage ratio of -10.16 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended March 31, 2026. Return on assets (ROA) is negative at -179.01, reflecting losses generated across the asset base. The company generates approximately 4,476.19 in revenue per employee across its workforce of 21.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, AIM ImmunoTech Inc.'s stock has declined approximately 93.39% over the past 52 weeks. The 50-day moving average sits at 0.21, while the 200-day moving average is 0.53.

Over the twelve months ended March 31, 2026, AIM ImmunoTech Inc. generated 94,000.00 in revenue and converted that into -13.28M in net income, yielding earnings per share of -5.17. EBITDA reached -10.08M, while operating income came in at -10.27M.

As of March 31, 2026, AIM ImmunoTech Inc. holds 5.88M in cash and equivalents against 4.57M in total debt, resulting in a net debt position of -1.60M. Total book value stands at 2.13M, with working capital of 69,000.00 providing operational flexibility.

AIM ImmunoTech Inc. produced -11.31M in operating cash flow over the twelve months ended March 31, 2026. After subtracting - - in capital expenditures, free cash flow totaled -11.31M - equivalent to -4.40 per share.

Over the twelve months ended March 31, 2026, AIM ImmunoTech Inc. posted a gross margin of -29.79, reflecting its pricing power and cost economics. The operating margin of -10,926.60 and net profit margin of -14,123.40 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -794.72: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -336.15, meaning AIM ImmunoTech Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

AIM ImmunoTech Inc.'s most recent stock split took place on June 16, 2025 with a 100:1 split ratio.

As of March 31, 2026, AIM ImmunoTech Inc. has an Altman Z-Score of -94.20, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.